News stories about Calithera Biosciences (NASDAQ:CALA) have been trending somewhat positive on Sunday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.5587085698886 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

CALA has been the subject of a number of recent research reports. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 price objective for the company in a research note on Monday, November 6th. William Blair initiated coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They issued an “outperform” rating for the company. ValuEngine lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Friday. Finally, BidaskClub upgraded shares of Calithera Biosciences from a “strong sell” rating to a “sell” rating in a research note on Friday, August 18th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $15.17.

Calithera Biosciences (NASDAQ CALA) traded down $0.15 on Friday, hitting $10.35. 490,579 shares of the stock were exchanged, compared to its average volume of 1,015,732. Calithera Biosciences has a 12-month low of $2.90 and a 12-month high of $20.05.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The firm had revenue of $7.20 million for the quarter, compared to analysts’ expectations of $6.02 million. sell-side analysts anticipate that Calithera Biosciences will post -0.77 earnings per share for the current fiscal year.

In other news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.30% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Calithera Biosciences (CALA) Receives Daily News Sentiment Score of 0.14” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/12/03/calithera-biosciences-cala-receives-daily-news-sentiment-score-of-0-14.html.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Insider Buying and Selling by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Stock Ratings for Calithera Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc and related stocks with our FREE daily email newsletter.